Literature DB >> 25483091

Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.

Yuxia Cui1, Stela S Palii, Cynthia L Innes, Richard S Paules.   

Abstract

DNA damage response (DDR) to double strand breaks is coordinated by 3 phosphatidylinositol 3-kinase-related kinase (PIKK) family members: the ataxia-telangiectasia mutated kinase (ATM), the ATM and Rad3-related (ATR) kinase and the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs). ATM and ATR are central players in activating cell cycle checkpoints and function as an active barrier against genome instability and tumorigenesis in replicating cells. Loss of ATM function is frequently reported in various types of tumors, thus placing more reliance on ATR for checkpoint arrest and cell survival following DNA damage. To investigate the role of ATR in the G2/M checkpoint regulation in response to ionizing radiation (IR), particularly when ATM is deficient, cell lines deficient of ATM, ATR, or both were generated using a doxycycline-inducible lentiviral system. Our data suggests that while depletion of ATR or ATM alone in wild-type human mammary epithelial cell cultures (HME-CCs) has little effect on radiosensitivity or IR-induced G2/M checkpoint arrest, depletion of ATR in ATM-deficient cells causes synthetic lethality following IR, which correlates with severe G2/M checkpoint attenuation. ATR depletion also inhibits IR-induced autophagy, regardless of the ATM status, and enhances IR-induced apoptosis particularly when ATM is deficient. Collectively, our results clearly demonstrate that ATR function is required for the IR-induced G2/M checkpoint activation and subsequent survival of cells with ATM deficiency. The synthetic lethal interaction between ATM and ATR in response to IR supports ATR as a therapeutic target for improved anti-cancer regimens, especially in tumors with a dysfunctional ATM pathway.

Entities:  

Keywords:  ATM and Rad3-related (ATR); ATM, the ataxia-telangiectasia mutated kinase; ATP, adenosine triphosphate; ATR, the ATM and Rad3-related; CHK1, the checkpoint kinase 1; CHK2, the checkpoint kinase 2; DAPI, 4′,6-diamidino-2-phenylindole; DDR, DNA damage response; DNA damage response; DNA-PKcs, the catalytic subunit of the DNA-dependent protein kinase; DSBs, double strand breaks; G2/M checkpoint; HME-CCs, human mammary epithelial cell cultures; IR, ionizing radiation; RMI, relative mitotic index; SSBs, single strand breaks; WT, Wild-type; ionizing radiation; synthetic lethality

Mesh:

Substances:

Year:  2014        PMID: 25483091      PMCID: PMC4615027          DOI: 10.4161/15384101.2014.960729

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

1.  Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance.

Authors:  Eric J Brown; David Baltimore
Journal:  Genes Dev       Date:  2003-03-01       Impact factor: 11.361

2.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

3.  Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice.

Authors:  A de Klein; M Muijtjens; R van Os; Y Verhoeven; B Smit; A M Carr; A R Lehmann; J H Hoeijmakers
Journal:  Curr Biol       Date:  2000-04-20       Impact factor: 10.834

4.  The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Authors:  Remko Prevo; Emmanouil Fokas; Philip M Reaper; Peter A Charlton; John R Pollard; W Gillies McKenna; Ruth J Muschel; Thomas B Brunner
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

Review 5.  Targeting the S and G2 checkpoint to treat cancer.

Authors:  Tao Chen; Peter A Stephens; Fiona K Middleton; Nicola J Curtin
Journal:  Drug Discov Today       Date:  2011-12-15       Impact factor: 7.851

6.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality.

Authors:  E J Brown; D Baltimore
Journal:  Genes Dev       Date:  2000-02-15       Impact factor: 11.361

Review 7.  Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family.

Authors:  M Raymond V Finlay; Roger J Griffin
Journal:  Bioorg Med Chem Lett       Date:  2012-07-01       Impact factor: 2.823

Review 8.  Targeting DNA repair mechanisms in cancer.

Authors:  John M Furgason; El Mustapha Bahassi
Journal:  Pharmacol Ther       Date:  2012-10-27       Impact factor: 12.310

9.  Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.

Authors:  Rebeka Sultana; Tarek Abdel-Fatah; Christina Perry; Paul Moseley; Nada Albarakti; Vivek Mohan; Claire Seedhouse; Stephen Chan; Srinivasan Madhusudan
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

10.  Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.

Authors:  E Fokas; R Prevo; J R Pollard; P M Reaper; P A Charlton; B Cornelissen; K A Vallis; E M Hammond; M M Olcina; W Gillies McKenna; R J Muschel; T B Brunner
Journal:  Cell Death Dis       Date:  2012-12-06       Impact factor: 8.469

View more
  12 in total

Review 1.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

Review 2.  Precision medicine for metastatic breast cancer--limitations and solutions.

Authors:  Monica Arnedos; Cecile Vicier; Sherene Loi; Celine Lefebvre; Stefan Michiels; Herve Bonnefoi; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2015-07-21       Impact factor: 66.675

3.  SPOP regulates the DNA damage response and lung adenocarcinoma cell response to radiation.

Authors:  Yiping Dong; Dan Zhang; Mengjiao Cai; Zhenzhen Luo; Yue Zhu; Liuyun Gong; Yutiantian Lei; Xinyue Tan; Qing Zhu; Suxia Han
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

Review 4.  Directing the use of DDR kinase inhibitors in cancer treatment.

Authors:  Inger Brandsma; Emmy D G Fleuren; Chris T Williamson; Christopher J Lord
Journal:  Expert Opin Investig Drugs       Date:  2017-10-14       Impact factor: 6.206

5.  Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells.

Authors:  Anna Strzeszewska; Olga Alster; Grażyna Mosieniak; Agata Ciolko; Ewa Sikora
Journal:  Cell Death Dis       Date:  2018-01-19       Impact factor: 8.469

Review 6.  Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.

Authors:  Lin Mei; Junran Zhang; Kai He; Jingsong Zhang
Journal:  J Hematol Oncol       Date:  2019-04-24       Impact factor: 17.388

7.  Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Authors:  Samuel J Klempner; Munveer S Bhangoo; Hubert Y Luu; Seung Tae Kim; Joseph Chao; Kyoung-Mee Kim; Jeeyun Lee
Journal:  J Gastrointest Oncol       Date:  2018-12

Review 8.  The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice.

Authors:  Luigia Stefania Stucci; Valeria Internò; Marco Tucci; Martina Perrone; Francesco Mannavola; Raffaele Palmirotta; Camillo Porta
Journal:  Genes (Basel)       Date:  2021-05-13       Impact factor: 4.096

Review 9.  Selective Autophagy Regulates Cell Cycle in Cancer Therapy.

Authors:  Kai Zheng; Zhendan He; Kaio Kitazato; Yifei Wang
Journal:  Theranostics       Date:  2019-01-01       Impact factor: 11.556

10.  Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice.

Authors:  Masahiro Uehara; Tetsuro Kusaba; Tomoharu Ida; Kunihiro Nakai; Tomohiro Nakata; Aya Tomita; Noriko Watanabe-Uehara; Kisho Ikeda; Takashi Kitani; Noriyuki Yamashita; Yuhei Kirita; Satoaki Matoba; Benjamin D Humphreys; Keiichi Tamagaki
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.